FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ―
― Completed enrollment in 6 mg and 2 mg dose cohorts of the Phase 1b trial of FTX-6058 in SCD; enrollment ongoing in 12 mg dose cohort ―― Additional FTX-6058 data from 6 mg cohort of ongoing Phase 1b trial show clinically relevant HbF increases of up to 9.5% ―
― Plan to complete enrollment in Phase 3 REACH trial of losmapimod in FSHD during 2H’23
― Fulcrum announces CEO transition; Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum has been appointed as interim CEO as Bryan Stuart departs to pursue other opportunities ―
― Presentation at J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST/7:30 p.m. EST ―
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.